2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer

Lanxin Zhang; Zihui Gao; hanshan Zhao; Ning Li; Jiapeng Han; Zuowei Zhao; Man Li

doi:null

您当前的位置：

首页 >

文章列表页 >

2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer

更新时间：2026-01-29

- 2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer
- “The latest research promotes the transformation of HR+/HER2- breast cancer treatment to precision and dynamic, bringing more lasting disease control and long-term survival benefits to patients.”
- Chin Oncol (2026)
- 作者机构：
  
  1.大连医科大学附属第二医院乳腺肿瘤科，辽宁省大连市，116023
  2.大连医科大学，辽宁省大连市，116044
  3.大连大学，辽宁省大连市，116622
- 作者简介：
  
  Zuowei Zhao E-mail:dlzhaozw@163.com。
  Man Li E-mail:man_li@dmu.edu.cn
- 基金信息：
  
  National Natural Science Foundation of China(基金编号82473449);National Natural Science Foundation of China(基金编号82503885);National Natural Science Foundation of China(基金编号82274296);Liaoning Provincial Staff Innovation Studio;Liaoning Provincial Natural Science Foundation for Doctoral Start-up Projects;China Research Fund for Optimal Diagnosis and Treatment of HR+/HER2− Early Breast Cancer;Beijing CSCO Cancer Research Project;The "1+X" Large Cohort Study of The Second Affiliated Hospital of Dalian Medical University(基金编号2022DXDL03)
- DOI：
  CLC： R737.9
- Received：23 January 2026，
- 稿件说明：
移动端阅览
张蓝心，高子慧，赵姗姗，等。2025年HR+/HER2-乳腺癌诊疗盘点。中国癌症杂志，2026,36.

Lanxin Zhang,Zihui Gao,Shanshan Zhao,et al.2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer.China Oncol,2026,36.
张蓝心，高子慧，赵姗姗，等。2025年HR+/HER2-乳腺癌诊疗盘点。中国癌症杂志，2026,36. DOI：

Lanxin Zhang,Zihui Gao,Shanshan Zhao,et al.2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer.China Oncol,2026,36. DOI：

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

AI导读

AI问答

⁰

2025 Review of Endocrine Therapy for HR+/HER2− Breast Cancer

DOI：